Dr. Chris Licskai, Western University, London, ON
Targeted asthma therapies are improving the lives of people with severe eosinophilic asthma. This symposium will define severe asthma, outline how biomarkers are applied to phenotype patients with asthma and how new biologic therapies are impacting patients with asthma. The approach to phenotyping severe eosinophilic asthma and the evidence demonstrating efficacy will be emphasized. Case examples will highlight the practical application of symposium content.
At the end of the session, participants will be able to:
- Apply clinical strategies to differentiate between uncontrolled and severe asthma
- Understand asthma treatment based on phenotypes
- Apply new biologic therapies to severe eosinophilic asthma
This symposium was co-developed by the CTS and AstraZeneca and was planned to achieve scientific integrity, objectivity and balance.